EAM
CLPT icon

Exome Asset Management’s ClearPoint Neuro CLPT Stock Holding History

Exome Asset Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Buy
+83,636
New +$1.04M 0.92% 40

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM

Exome Asset Management's CLPT Position: Q2 2026 in Review

Exome Asset Management opened a new position in ClearPoint Neuro (CLPT) in Q2 2026: 83,636 shares worth $1.49M. The stake represents 0.92% of the portfolio and ranks #40 among its holdings.

129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Exome Asset Management held 83,636 shares of ClearPoint Neuro worth $1.49M as of Q2 2026.
  • ClearPoint Neuro was a new Exome Asset Management position in Q2 2026.
  • ClearPoint Neuro made up 0.92% of Exome Asset Management's portfolio in Q2 2026, its #40 holding.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.